Condition

NSCLC (Non-small Cell Lung Cancer) clinical trials and research

• 44Clinical trials
• 27Countries

Newest NSCLC (Non-small Cell Lung Cancer) clinical trials

All recruiting trials (44)

• TS-104: a first-in-human, dose-escalation study for advanced solid tumors

  This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.

  Recruiting at 3 sites Phase 1 TwoStep Therapeutics, Inc. · Maumee, Ohio and 2 other locations · NCT07814248

• Icotinib after surgery for early EGFR-mutant NSCLC

  This study tests whether giving icotinib after surgery helps patients with early-stage EGFR-mutant NSCLC compare to just following them after surgery.

  Recruiting at 2 sites Betta Pharmaceuticals Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT07806604

• Oral Paclitaxel with Immunotherapy and SBRT as Neoadjuvant Treatment for Older Adults with NSCLC

  This trial tests a new, lighter neoadjuvant therapy that combines an oral paclitaxel solution, an immune checkpoint inhibitor, and SBRT for adults aged 70 and older with resectable NSCLC to see if it can shrink tumors before surgery.

  Recruiting Phase 4 Shanghai Pulmonary Hospital, Shanghai, China · Guangzhou, Guangdong and 4 other locations · NCT07754812

• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC

  This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.

  Recruiting Phase 2 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07742332

• Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors

  This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.

  Recruiting at 2 sites Phase 4 Rigel Pharmaceuticals · Logroño, La Rioja and 1 other locations · NCT07704658

• GFH375 vs. Docetaxel for KRAS G12D-mutant NSCLC

  This study tests whether GFH375 can help people with KRAS G12D-mutant NSCLC more than docetaxel.

  Recruiting Phase 3 Genfleet Therapeutics (Shanghai) Inc. · Shanghai, Shanghai Municipality · NCT07668752

• Bright light therapy to help time immune therapy for melanoma and NSCLC

  A feasibility test of daily 60-minute bright light therapy before starting first-line immune checkpoint therapy for melanoma or NSCLC.

  Recruiting Weill Medical College of Cornell University · New York, New York · NCT07661966

• Hypofractionated chemoradiotherapy with tislelizumab and surufatinib for unresectable stage III NSCLC

  This phase 2 trial tests whether adding tislelizumab and surufatinib to hypofractionated chemoradiotherapy helps patients with unresectable stage III NSCLC, compared to tislelizumab alone after radiotherapy.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07609121

• Serplulimab Monotherapy in Elderly NSCLC Patients with High PD-L1 (≥50%)

  This study tests whether serplulimab alone can help older adults with NSCLC who have high PD-L1 levels (≥50%).

  Recruiting Phase 2 Tang-Du Hospital · Xi'an, Shannxi · NCT07596121

• Microwave ablation plus tislelizumab and docetaxel for advanced NSCLC after first-line immunotherapy progression

  This treatment tests whether adding microwave ablation to tislelizumab and docetaxel can help people with advanced non‑small cell lung cancer whose disease progressed after first‑line immunotherapy plus chemotherapy.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07528274

• EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma

  This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.

  Recruiting at 8 sites Phase 1 EpiBiologics · Los Angeles, California and 7 other locations · NCT07462377

• Single‑session high‑dose lung radiotherapy and its effects on outcomes and quality of life

  This study tests whether a single high‑dose session of SBRT (30–34 Gy) works and how it affects quality of life for adults with small primary non‑small cell lung cancers or up to three lung metastases who are inoperable or refuse surgery.

  Recruiting Institut du Cancer de Montpellier - Val d'Aurelle · Montpellier, ICM and 1 other locations · NCT07441941

• TGI-5 alone and with nivolumab for advanced or metastatic solid tumors

  This trial tests whether TGI-5 by itself or combined with nivolumab is safe and can shrink tumors in adults with advanced or metastatic colorectal cancer, melanoma, hepatocellular carcinoma, or non‑small cell lung cancer who have exhausted standard treatments.

  Recruiting Phase 1 Hefei TG ImmunoPharma Co., Ltd. · Shanghai · NCT07376707

• Neoadjuvant ensartinib plus chemotherapy for resectable ALK-positive NSCLC

  This will test whether taking ensartinib with chemotherapy before surgery helps people with stage II–IIIB (N2) ALK-positive, resectable non-small cell lung cancer.

  Recruiting Phase 1/2 Tang-Du Hospital · Xi’an, Shanxi · NCT07354061

• WAST cell plus docetaxel for PD‑1–resistant advanced non‑small cell lung cancer

  This will test whether infusions of WAST immune cells combined with docetaxel chemotherapy can shrink tumors or slow progression in people with advanced NSCLC that stopped responding to PD‑1 inhibitors.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07330050

• Predicting Immunotherapy Response from Live Tumor Biopsies

  This project will try to see if analyzing live tumor biopsy samples kept in their 3D environment can predict whether people with advanced solid tumors will respond to immunotherapy.

  Recruiting at 7 sites Elephas · Fort Smith, Arkansas and 7 other locations · NCT07327489

• 177Lu-BetaBart treatment for relapsed, inoperable, or metastatic solid tumors

  This trial will test a radioactive antibody called 177Lu-BetaBart in adults whose solid tumors have progressed after prior treatment, including castration-resistant prostate, colorectal, lung, ovarian, or cervical cancer.

  Recruiting at 5 sites Phase 1/2 Radiopharm Theranostics, Ltd · Dothan, Alabama and 4 other locations · NCT07189871

• Early feasibility test of the CAROL device for treating small (≤2 cm) stage 1 NSCLC lung tumors

  This study will test the CAROL device in adults with stage 1 non-small cell lung cancer (tumors ≤2 cm) to see if the treatment can be used safely.

  Recruiting Tau-MEDICAL Co., Ltd. · Melbourne, Victoria · NCT07122258

• Adaptive adjuvant sintilimab treatment guided by MRD for resected Stage II–IIIB NSCLC

  This trial tests whether using postoperative blood MRD tests to guide adjuvant sintilimab helps people with resected Stage II–IIIB NSCLC who did not achieve a complete response after neoadjuvant chemo‑immunotherapy.

  Recruiting at 2 sites Phase 2 Guangdong Association of Clinical Trials · Guangzhou, Guangdong and 1 other locations · NCT07120698

• Testing GV20-0251 for advanced or treatment‑resistant solid tumors

  This study will test whether GV20-0251 is safe and tolerable when given every three weeks to adults with advanced or treatment‑resistant solid tumors such as liver, lung, pancreatic cancer, and melanoma.

  Recruiting Phase 1 West China Hospital · Chengdu, Sichuan · NCT07106827

• PLB1004 with platinum-based chemotherapy in EGFR-mutant NSCLC

  This study tests whether adding PLB1004 to standard platinum-based chemotherapy helps people with EGFR-mutant non-small cell lung cancer live longer or control their cancer better.

  Recruiting at 2 sites Phase 1/2 Avistone Pharmaceutical（Ningbo）Co., LTD. · Zhengzhou, Henan and 1 other locations · NCT07063329

• D-BACE plus chemotherapy and camrelizumab for resectable stage II–IIIA and potentially resectable T3–4N2 IIIB non-small cell lung cancer

  This study will see if adding D-BACE (drug-eluting bead bronchial arterial chemoembolization) to standard neoadjuvant chemotherapy and camrelizumab helps adults with resectable stage II–IIIA or potentially resectable T3–4N2 IIIB NSCLC respond better before surgery.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07016126

• Radical lung tumor removal with lymph node dissection on both sides for N3 NSCLC

  This trial will test whether removing the lung tumor plus lymph nodes from both sides of the chest helps people with N3 non-small cell lung cancer live longer and reduce recurrence.

  Recruiting Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Shanghai, Shanghai Municipality and 1 other locations · NCT07003490

• Using Torque Teno Virus levels to predict treatment response in lung cancer patients

  This study is testing if measuring Torque Teno Virus levels in the blood can help predict how well lung cancer patients respond to a specific type of treatment.

  Recruiting Medical University of Vienna · Vienna · NCT06967532

• Cryoablation with Tislelizumab and Chemotherapy for Non-small Cell Lung Cancer

  This study is testing if combining a freezing treatment with a new drug and chemotherapy can help people with early-stage lung cancer before surgery and improve their chances of survival.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT06939127

• Evaluating daraxonrasib for previously treated patients with RAS mutated lung cancer

  This study is testing if a new drug called daraxonrasib can help people with RAS mutated lung cancer live longer and feel better compared to standard chemotherapy.

  Recruiting at 26 sites Phase 3 Revolution Medicines, Inc. · Birmingham, Alabama and 198 other locations · NCT06881784

• Evaluating befotertinib for advanced non-small cell lung cancer with specific EGFR mutations

  This study is testing a new drug called befotertinib to see if it can help people with advanced lung cancer who have specific types of EGFR mutations after other treatments haven't worked.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT06863506

• Investigating ALTA3263 for advanced solid tumors with KRAS mutations

  This study is testing a new oral medication called ALTA3263 to see if it is safe and effective for adults with advanced solid tumors that have KRAS mutations.

  Recruiting at 14 sites Phase 1 Alterome Therapeutics, Inc. · Orlando, Florida and 13 other locations · NCT06835569

• Evaluating SIM0505 for advanced solid tumors

  This study is testing a new treatment called SIM0505 to see if it is safe and effective for adults with advanced solid tumors that haven't responded to other therapies.

  Recruiting at 6 sites Phase 1 NextCure, Inc. · Orlando, Florida and 16 other locations · NCT06792552

• Cognitive screening for lung cancer patients

  This study is trying to see if lung cancer and its treatments affect thinking skills in patients during their first year after diagnosis.

  Recruiting European Institute of Oncology · Milan · NCT06727370

• Investigating KQB365 for treating advanced solid tumors

  This study tests if a new treatment called KQB365, alone or with another drug, can help adults with advanced solid tumors that have specific genetic mutations.

  Recruiting at 11 sites Phase 1 Kumquat Biosciences Inc. · Phoenix, Arizona and 10 other locations · NCT06720987

• Investigating KQB365 for treating advanced solid tumors

  This study tests if a new treatment called KQB365, alone or with another drug, can help adults with advanced solid tumors that have specific genetic mutations.

  Recruiting at 11 sites Phase 1 Kumquat Biosciences Inc. · Phoenix, Arizona and 10 other locations · NCT06720987

• AI model to predict hidden lymph node cancer in lung patients

  This study is testing a new AI tool to see if it can find hidden cancer in lymph nodes for people with early-stage lung cancer to help doctors make better treatment choices.

  Recruiting Fudan University · Shanghai · NCT06684418

• Evaluating a new CAR T-cell therapy for solid tumors expressing EGFR

  This study is testing a new CAR T-cell therapy to see if it can safely help adults with certain solid tumors, like colorectal and lung cancer, that have specific markers.

  Recruiting at 10 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 9 other locations · NCT06682793

• Treatment for extensive small cell lung cancer using chemotherapy and immunotherapy

  This study is testing a new combination of chemotherapy and immunotherapy to see if it helps people with extensive small cell lung cancer who haven't had treatment before.

  Recruiting Phase 2 Shaare Zedek Medical Center · Jerusalem, Israel · NCT06667167

• Comparing AK104 and Sugemalimab for advanced lung cancer treatment

  This study is testing whether a new treatment called AK104 works better than Sugemalimab for people with advanced lung cancer who haven't seen their disease get worse after chemotherapy and radiation.

  Recruiting Phase 3 Akeso · Jinan · NCT06617416

• Evaluating the safety and effectiveness of YH42946 for advanced solid tumors

  This study is testing a new oral medication called YH42946 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 7 sites Phase 1/2 Yuhan Corporation · Fairfax, Virginia and 7 other locations · NCT06616766

• Collecting samples from patients with certain types of cancer to improve detection and treatment.

  This study is collecting blood and tissue samples from patients with certain types of cancer to see if it can help improve how we detect cancer and understand the risk of it coming back.

  Recruiting at 47 sites Paradigm Health · Birmingham, Alabama and 46 other locations · NCT06605404

• Evaluating XB010 for patients with solid tumors

  This study is testing a new drug called XB010, alone and with another medication, to see if it can help people with advanced solid tumors who have few other treatment options.

  Recruiting at 18 sites Phase 1 Exelixis · Irvine, California and 19 other locations · NCT06545331

• Evaluating IAM1363 for HER2-related cancers

  This study is testing a new treatment called IAM1363 to see if it can help people with advanced cancers that have changes in the HER2 gene.

  Recruiting at 53 sites Phase 1 Iambic Therapeutics, Inc · La Jolla, California and 52 other locations · NCT06253871

• Testing OSE-279 for advanced solid tumors and lymphomas

  This study is testing a new treatment called OSE-279 to see if it can help people with advanced solid tumors or lymphomas who haven't had success with other therapies.

  Recruiting at 10 sites Phase 1/2 OSE Immunotherapeutics · Anderlecht and 10 other locations · NCT05751798

• Treatment with STAR0602 for advanced solid tumors

  This study is testing a new treatment called STAR0602 to see if it can help people with advanced solid tumors by looking at how safe it is and how well it works.

  Recruiting at 16 sites Phase 1/2 Marengo Therapeutics, Inc. · Sacramento, California and 18 other locations · NCT05592626

• Evaluating PC14586 for advanced solid tumors with a specific mutation

  This study is testing a new oral medication called PC14586 to see if it can help people with advanced solid tumors that have a specific mutation in the TP53 gene.

  Recruiting at 71 sites Phase 1/2 PMV Pharmaceuticals, Inc · Irvine, California and 75 other locations · NCT04585750

• Testing a new drug for advanced solid tumors

  This study is testing a new drug for people with advanced solid tumors, like breast or prostate cancer, to see how safe it is and how well it works on its own or with other treatments.

  Recruiting at 11 sites Phase 2 Pfizer · Los Angeles, California and 38 other locations · NCT04557449

Related topics

Quick answers

How many NSCLC (Non-small Cell Lung Cancer) clinical trials are recruiting right now?

44, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 27 countries. The most sites are in China (21 trials), United States (18 trials), France (6 trials), Spain (6 trials), United Kingdom (5 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 11, Phase 1: 10, Phase 1/2: 8, Phase 3: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →